{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:40Z","timestamp":1791216520781,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp;amp; Metabol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/Introduction<\/jats:title>\n                    <jats:p>Glucotoxicity exacerbates hyperglycemia by impairing insulin secretion and sensitivity, necessitating effective interventions. Although short\u2010term intensive insulin therapy (SIIT) mitigates glucotoxicity, the effect of combining SIIT with sodium\u2010glucose co\u2010transporter 2 (SGLT2) inhibitors in hospitalised type 2 diabetes mellitus (T2DM) patients with severe hyperglycemia remains unclear. Herein, we aimed to evaluate the efficacy and safety of combining SGLT2 inhibitors with basal bolus therapy (BBT) for glycemic control in hospitalised patients with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      In this randomised, open\u2010label, single\u2010centre trial, 35 eligible T2DM patients hospitalised for treating hyperglycemia were allocated to the BBT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) or BBT with empagliflozin (BBT\u2009+\u2009E) groups (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918). Patients were monitored for 7\u2009days using flash glucose monitoring. The primary outcome was time\u2010in\u2010range (TIR, 70\u2013180\u2009mg\/dL). The secondary outcomes included time\u2010above\u2010range (TAR), time\u2010below\u2010range (TBR), daily glucose levels, total daily insulin dose and ketone body concentration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The BBT\u2009+\u2009E group exhibited a significantly higher TIR from day\u20092, which exceeded 70% by day\u20095, with reduced TAR and insulin requirements. Blood glucose levels declined more rapidly in the BBT\u2009+\u2009E group, accompanied by a modest ketone elevation without severe ketoacidosis. The TBR increased marginally on day\u20097, primarily nocturnally; but no symptomatic hypoglycaemia occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The addition of SGLT2 inhibitors to BBT significantly improved early glycaemic control and reduced insulin requirements without severe ketone elevation in hospitalised T2DM patients. Routine monitoring of ketone levels and careful insulin titration are critical to ensure safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/edm2.70096","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:09:59Z","timestamp":1755626999000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating Intensive Insulin Therapy With Empagliflozin in Type 2 Diabetes: A Randomised Study"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-6885","authenticated-orcid":false,"given":"Nobutoshi","family":"Fushimi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes Ichinomiyanishi Hospital  Ichinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hachiya","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Ichinomiyanishi Hospital  Ichinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Iwasaka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Ichinomiyanishi Hospital  Ichinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machi","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Ichinomiyanishi Hospital  Ichinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Masamura","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Ichinomiyanishi Hospital  Ichinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Ichinomiyanishi Hospital  Ichinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Ichinomiyanishi Hospital  Ichinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.13.6.610"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0075"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60762-X"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01129.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70006-8"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666160627102516"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1033"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0029"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886"},{"issue":"5","key":"e_1_2_12_11_1","article-title":"Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium\u2010Glucose Cotransporter 2 Inhibitors","volume":"105","author":"Fleming N.","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2021.04.006"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0289"},{"issue":"3","key":"e_1_2_12_14_1","first-page":"91","article-title":"Nutritional Guidance for Patients With Diabetes: Consensus Statement of the Japan Diabetes Society","volume":"63","author":"Yamauchi T.","year":"2020","journal-title":"Journal of the Japan Diabetes Society"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0295"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1407"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1988"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13093"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12994"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2597"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000270"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13355"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3423w"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4097469"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12785"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1131121"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12588"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0392"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05815-1"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1356"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574887113666180314101436"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12457"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002"},{"issue":"1","key":"e_1_2_12_35_1","first-page":"S109","article-title":"When Insulin Therapy Fails: The Impact of SGLT2 Inhibitors in Patients With Type 2 Diabetes","volume":"40","author":"Harris S.","year":"2017","journal-title":"Diabetes Care"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.589702"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2288897"},{"issue":"5","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"e00910","DOI":"10.1002\/prp2.910","article-title":"Risk of Genital and Urinary Tract Infections Associated With SGLT\u20102 Inhibitors as an Add\u2010On Therapy to Metformin in Patients With Type 2 Diabetes Mellitus: A Retrospective Cohort Study in Korea","volume":"10","author":"Yang H.","year":"2022","journal-title":"Pharmacology Research & Perspectives"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:06:09Z","timestamp":1764828369000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/edm2.70096"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70096","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"2025-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70096"}}